本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励计划或 员工持股计划。本次回购金额不超过人民币 30,000 万元（含），不低于人民币 15,000 万元（含），回购价格不超过 5.20 元/股（含）。根据最高回购规模、回 购价格上限测算，预计回购股份数量为 5,769.23 万股，约占公司目前总股本的 5.34%。具体内容详见公司于 2024 年 1 月 16 日披露于指定信息披露媒体及巨潮 资讯网（http://www.cninfo.com.cn）上的《关于以集中竞价交易方式回购公司股 份方案的公告》（公告编号：2024-007）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定，回购期间，上市公司应当在每个月的前三个交 易日内披露截至上月末的回购进展情况。现将公司回购股份的进展情况公告 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥2.53 billion, representing a 0.76% increase compared to ¥2.51 billion in 2022[24]. - The net profit attributable to shareholders for 2023 was approximately ¥47.45 million, a significant turnaround from a loss of ¥176 million in 2022, marking a 126.97% improvement[24]. - The net cash flow from operating activities increased by 9.57% to approximately ¥413.55 million in 2023, up from ¥377.42 million in 2022[24]. - Basic and diluted earnings per share for 2023 were both ¥0.04, compared to a loss of ¥0.16 per share in 2022, reflecting a 125% increase[24]. - Total assets at the end of 2023 were approximately ¥3.90 billion, a 0.59% increase from ¥3.88 billion at the end of 2022[24]. - The net assets attributable to shareholders increased by 3.40% to approximately ¥1.59 billion at the end of 2023, compared to ¥1.54 billion at the end of 2022[24]. - The company achieved a total revenue of 2.528 billion yuan in 2023, representing a growth of 0.76% compared to 2022[40]. - The main business revenue reached 2.413 billion yuan, an increase of 3.07% year-on-year, with milk powder sales generating 2.337 billion yuan, up 2.66%[40]. Market and Competitive Position - The company reported a significant decline in newborn numbers, impacting the infant formula market, with intensified brand competition and high operational costs[4]. - The company is focused on expanding its market presence and increasing sales scale through resource utilization[4]. - The company is positioned to benefit from the growing demand for infant formula in lower-tier cities and towns, indicating significant future growth potential[42]. - The company has established a full industry chain layout integrating R&D, production, and sales, ensuring high-quality products for consumers[37]. - The company is leveraging data empowerment to enhance market competitiveness and operational efficiency[42]. Product Development and Quality Assurance - The company emphasizes the importance of product quality and safety, implementing advanced detection equipment and technology for quality control[7]. - The company maintains a commitment to quality assurance, ensuring food safety throughout the production process[7]. - The company continues to focus on R&D for new products, including special medical formula milk powder and various nutritional products[38]. - The implementation of new national standards for infant formula foods is expected to enhance industry concentration and improve product quality[36]. - The company has completed the registration of all infant formula products under the new national standards[42]. Cost Management and Operational Efficiency - The company plans to enhance cost management and expense control to improve competitiveness in the market[4]. - The company aims to strengthen accounts receivable collection and improve asset liquidity management to mitigate financial risks[5]. - The gross profit margin improved to 47.07%, up by 1.19 percentage points year-on-year, primarily due to reduced sales discounts and increased sales of high-margin products[54]. - The company is focused on enhancing operational efficiency by optimizing its industrial layout and reducing operational costs through standardized systems and information processes[102]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[4]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[116]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring autonomous operational capabilities[119]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors through designated platforms[114]. - The company revised its governance documents to enhance decision-making processes and protect investor rights, aligning with the latest legal requirements[118]. Shareholder Engagement and Management - The company held three shareholder meetings during the reporting period, ensuring equal treatment of all shareholders and facilitating their participation[110]. - The board of directors convened eight meetings, with a composition of 8 members, including 3 independent directors, complying with legal and regulatory requirements[112]. - The company reported a total of 58,000 shares held by executives at the end of the reporting period, with no changes in shareholding during the period[123]. - The company’s independent directors maintained independence and focused on protecting the interests of minority shareholders[142]. Environmental and Social Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[165]. - The company has implemented clean production practices and has passed certifications for clean production, energy management, and environmental management systems[165]. - The company has actively engaged in social responsibility initiatives, including the "Love Baby" project, which has been running since 1993 to support families with special needs children[166]. - The company emphasizes the importance of customer, employee, shareholder, partner, and social value in its core business philosophy[167]. Future Outlook and Strategic Initiatives - The company has provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[130]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on expanding the product line in the infant nutrition sector[130]. - Market expansion plans include entering three new provinces, which are projected to increase market share by 10%[130]. - The company is considering strategic acquisitions to enhance its supply chain efficiency and reduce costs, with a target of 200 million RMB in savings[130].

Financial Performance - The company's revenue for Q1 2024 was ¥720,455,358.38, representing a 2.28% increase compared to ¥704,386,288.42 in the same period last year[4] - Net profit attributable to shareholders increased by 80.71% to ¥22,074,986.63 from ¥12,215,392.19 year-on-year[4] - The net profit after deducting non-recurring gains and losses surged by 368.90% to ¥18,462,398.06 from ¥3,937,353.49 in the previous year[4] - The net cash flow from operating activities rose by 247.68% to ¥82,577,692.15 compared to ¥23,750,966.73 in the same period last year[4] - Basic earnings per share doubled to ¥0.02 from ¥0.01 year-on-year, with diluted earnings per share also at ¥0.02[4] - The company experienced a 60.23% increase in total profit, reaching ¥2,917,000,000.00 compared to ¥1,818,000,000.00 in the previous year[9] - Total operating revenue for Q1 2024 was CNY 720,455,358.38, an increase of 2.5% compared to CNY 704,386,288.42 in Q1 2023[27] - The net profit for the first quarter of 2024 was CNY 24,465,526.74, an increase of 77.5% compared to CNY 13,801,717.67 in the same period last year[28] - The total comprehensive income for the first quarter was CNY 32,767,894.77, compared to CNY 18,574,924.34 in the same quarter last year, marking a growth of 76.5%[29] Assets and Liabilities - Total assets decreased by 2.82% to ¥3,790,024,889.41 from ¥3,900,099,864.43 at the end of the previous year[4] - Total assets as of March 31, 2024, were CNY 3,790,024,889.41, down from CNY 3,900,099,864.43 at the beginning of the year, a decrease of 2.8%[25] - Total liabilities decreased to CNY 2,160,285,680.11 from CNY 2,258,108,718.95, a decline of 4.3%[25] Cash Flow - The company's cash flow from financing activities increased by 183.71% to ¥21,000,000.00, driven by increased bank loans and recovery of pledged time deposits[12] - Cash and cash equivalents decreased to CNY 862,833,529.39 from CNY 1,028,429,231.04, a decline of 16.1%[23] - The cash flow from operating activities showed a net increase of CNY 82,577,692.15, significantly higher than CNY 23,750,966.73 in the previous year[30] - The company incurred a net cash outflow from investing activities of CNY 172,218,066.11, compared to CNY 14,525,597.70 in the previous year, indicating increased investment activity[30] - The financing activities resulted in a net cash outflow of CNY 71,985,957.99, compared to CNY 26,579,720.89 in the same period last year, showing a higher reliance on financing[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 67,832[15] - The largest shareholder, Beingmade Group Co., Ltd., holds 16.72% of the shares, totaling 180,629,471 shares, with 179,060,971 shares pledged[15] - The company has repurchased 34,897,768 shares, accounting for 3.23% of the total share capital[16] Research and Development - Research and development expenses decreased by 43.68% to ¥262,000,000.00 from ¥465,000,000.00 year-on-year[9] - Research and development expenses for Q1 2024 were CNY 2,623,635.13, down from CNY 4,658,720.72 in Q1 2023, a decrease of 43.8%[27] Legal and Regulatory Matters - A court has frozen 53,000,000 shares held by Beingmade Group, representing 26.98% of its total shares, due to a debt enforcement application[19] - 37,013,943 shares held by Beingmade Group are frozen by the court, accounting for 19.34% of its total shares, due to a prior pledge[21] - The company is required to pay approximately $18.5 million to FNOF Treasure Train Limited as per an arbitration ruling regarding the repurchase of shares in Beingmade Health Management Corp.[21] Other Developments - The company supports the establishment of an industrial incubation fund by its subsidiary to enhance investment risk management and strategic alignment[17] - As of the announcement date, the industrial fund's registration procedures have not been completed, and the company will disclose updates on significant matters[17] - The company has completed the deregistration of 13 out of 14 subsidiaries under Beingmade Marketing Management Co., Ltd.[18]

证券代码：002570 证券简称：贝因美 公告编号：2024-032 贝因美股份有限公司 关于控股股东及实际控制人涉诉的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司控股股东贝因美集团有限公司（以下简称"贝因美 集团"）质押/冻结上市公司股份数量为 179,105,171 股，占其所持公司股份总数 的 99.16%。 本案件执行措施涉及贝因美集团前期已质押予中航信托股份有限公司的 4,800 万本公司无限售流通股和贝因美集团前期已质押予中国建设银行股份有限 公司杭州高新支行的 500 万股无限售流通股。已被司法冻结的股份后续可能因司 法裁决而引起贝因美集团被动减持，非其主观意愿行为。公司将严格遵守相关规 定，及时履行信息披露义务。敬请广大投资者谨慎决策，注意投资风险。 贝因美股份有限公司（以下简称"公司"、"本公司"）今日收到公司控股股 东贝因美集团函告，贝因美集团、实际控制人谢宏及其关联方今日收到长城国融 投资管理有限公司（以下简称"长城国融"）出具的《债权转让通知书》。前期债 权债务涉诉事项具体内容详见公司 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-031 贝因美股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励计划或 员工持股计划。本次回购金额不超过人民币 30,000 万元（含），不低于人民币 15,000 万元（含），回购价格不超过 5.20 元/股（含）。根据最高回购规模、回 购价格上限测算，预计回购股份数量为 5,769.23 万股，约占公司目前总股本的 5.34%。具体内容详见公司于 2024 年 1 月 16 日披露于指定信息披露媒体及巨潮 资讯网（http://www.cninfo.com.cn）上的《关于以集中竞价交易方式回购公司股 份方案的公告》（公告编号：2024-007）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-030 贝因美股份有限公司 关于回购公司股份的进展公告 一、回购股份的进展情况 截至 2024 年 2 月 29 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 14,745,500 股，占公司总股本的 1.37%，最高成交价为 3.90 元/股，最低成交价为 2.90 元/股，成交总金额为 49,990,187.00 元（不含交易费 用）。 公司股份回购的实施符合公司回购方案及相关法律法规的要求。 二、其它说明 时段符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定。 1、公司未在下列期间回购公司股票： （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-029 贝因美股份有限公司 关于控股股东部分股份解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司控股股东贝因美集团有限公司质押/冻结上市公司 股份数量为 179,105,171 股，占其所持公司股份总数的 99.16%。请投资者注意相 关风险。 贝因美股份有限公司（以下简称"公司"、"本公司"）近日接到公司控股 股东贝因美集团有限公司（以下简称"贝因美集团"）关于将本公司部分股份解 除质押及质押的《告知函》，具体事项如下： 一、 股东本次解除质押及质押的基本情况 1、股份解除质押的基本情况 | 股东名称 | 是否为控股 | 本次解除质 | 质押开始 | 解除质押 | | 本次解除质 | 本次解除质 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东及一致 | 押股数 | 日期 | 日期 | 质权人 | 押占其所持 | 押占公司总 | | | 行动人 | （股） | | | | ...

证券代码：002570 证券简称：贝因美 公告编号：2024-028 贝因美股份有限公司 关于控股股东质押证券处置的进展公告 公司控股股东贝因美集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司控股股东贝因美集团有限公司及其一致行动人合计 持有 180,629,471 股上市公司股份，占上市公司总股本的 16.72%，其中，质押/ 冻结上市公司股份数量为 179,105,171 股，占其所持公司股份总数的 99.16%。请 投资者注意相关风险。 | 股东名称 | 股份性质 | 本次处置过户完成前 | | 本次处置过户完成后 | | | --- | --- | --- | --- | --- | --- | | | | 持股数量 | 占总股本 | 持股数量 | 占总股本 | | | | （股） | 比例 | （股） | 比例 | | 贝因美集团 | 合计持有股份 | 191,418,500 | 17.7232% | 180,629, ...

证券代码：002570 证券简称：贝因美 公告编号：2024-027 一、回购股份的进展情况 截至 2024 年 2 月 5 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 11,380,000 股，占公司总股本的 1.05%，最高成交价为 3.90 元/股，最低成交价为 2.99 元/股，成交总金额为 39,983,697.00 元（不含交易费 用）。 公司股份回购的实施符合公司回购方案及相关法律法规的要求。 二、其它说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时段符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定。 贝因美股份有限公司 关于回购公司股份达到1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，同意公 司使用自有资金或自筹资金以集中竞价交易方式回购公司已发行的人民币普通 股（A 股）股票。 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-026 贝因美股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励计划或 员工持股计划。本次回购金额不超过人民币 30,000 万元（含），不低于人民币 15,000 万元（含），回购价格不超过 5.20 元/股（含）。根据最高回购规模、回 购价格上限测算，预计回购股份数量为 5,769.23 万股，约占公司目前总股本的 5.34%。具体内容详见公司于 2024 年 1 月 16 日披露于指定信息披露媒体及巨潮 资讯网（http://www.cninfo.com.cn）上的《关于以集中竞价交易方式回购公司股 份方案的公告》（公告编号：2024-007）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的 ...